Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) Director Bvf Partners L. P/Il bought 22,110 shares of the company’s stock in a transaction dated Wednesday, January 11th. The shares were acquired at an average cost of $29.89 per share, for a total transaction of $660,867.90. Following the completion of the transaction, the director now owns 2,491,703 shares of the company’s stock, valued at approximately $74,477,002.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kymera Therapeutics Trading Up 2.9 %
NASDAQ:KYMR opened at $34.54 on Friday. The firm has a market capitalization of $1.90 billion, a PE ratio of -11.75 and a beta of 1.45. The stock has a 50 day moving average of $27.99 and a 200-day moving average of $26.52. Kymera Therapeutics, Inc. has a 52 week low of $13.15 and a 52 week high of $46.22.
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). The company had revenue of $9.55 million for the quarter, compared to the consensus estimate of $16.42 million. Kymera Therapeutics had a negative net margin of 334.72% and a negative return on equity of 34.20%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Hedge Funds Weigh In On Kymera Therapeutics
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on KYMR. Credit Suisse Group lowered Kymera Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $47.00 to $32.00 in a research report on Monday, December 5th. Wells Fargo & Company lifted their target price on Kymera Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. B. Riley upped their price objective on Kymera Therapeutics from $35.00 to $37.00 in a research note on Thursday, December 15th. Piper Sandler upped their price objective on Kymera Therapeutics from $43.00 to $58.00 in a research note on Wednesday, December 14th. Finally, The Goldman Sachs Group upped their price objective on Kymera Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 16th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $41.89.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.